neurofibrosarcoma

Now, a claim to a pharmaceutical composition comprising an idiotypic monoclonal antibody immmunologically reactive with a neurofibrosarcoma is the kind of "reach through" claim you seem to find objectionable, and there you are probably right on these facts.

Patent Docs 2008

Claim 92 of the Alonso patent application claims a "method of treating neurofibrosarcoma in a human by administering an effective amount" of an idiotypic monoclonal antibody (mAb) secreted in a human-human cell hybridoma.

Patent Law Blog (Patently-O) 2009

Claim 92 of the Alonso patent application claims a "method of treating neurofibrosarcoma in a human by administering an effective amount" of an idiotypic monoclonal antibody (mAb) secreted in a human-human cell hybridoma.

Patent Law Blog (Patently-O) 2009

A method of treating neurofibrosarcoma in a human by administering an effective amount of a monoclonal antibody idiotypic to the neurofibrosarcoma of said human, wherein said monoclonal antibody is secreted from a human-human hybridoma derived from the neurofibrosarcoma cells.

Patent Docs 2008

As I understand it, Alonso's method requires production of a specific mAb for each patient (a monoclonal antibody idiotypic to the neurofibrosarcoma of "said" human).

Patent Docs 2008

What Dr. Alonzo found was that for this particular type of cancer, neurofibrosarcoma, cells could be taken and used to make human idiotypic antibodies from the patient's own tumor, which could then be used to treat the patient with (admittedly) striking results.

Patent Docs 2008

Alonzo has provided one example of a useful antibody that shows his method of producing a self-tailored antibody for neurofibrosarcoma is enabled.

Patent Docs 2008

I assume Alonso claimed his method of producing specific monoclonal antibodies using that neurofibrosarcoma cell.

Patent Docs 2008

That is, it is not enough to describe [] the procedure for making a human-human hybridoma from neurofibrosarcoma, and teach how to determine whether a given antibody, specific to a patient's neurofibrosarcoma, will function in the claimed method.

Patent Docs 2008

The analogy here is Dr. Alonso's failure to disclose the structure of any neurofibrosarcoma-specific antigens, which analogy appears to disregard the significant distinctions between actual antigens expressed by these tumor cells and hypothetical inhibitors specific for COX-2.

Patent Docs 2008